Myk-461 pharmacokinetics
WebMyosin Myosins are a superfamily of motor proteins best known for their roles in muscle contraction and in a wide range of other motility processes in eukaryotes. They are ATP-dependent and responsible for actin-based motility. Web3 mrt. 2015 · The Phase 1 clinical trial will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single oral doses of MYK-461 in healthy volunteers. In parallel, MyoKardia has initiated a supplemental Phase 1 …
Myk-461 pharmacokinetics
Did you know?
Web6 okt. 2015 · MYK-461 demonstrated a dose-linear and dose-proportional pharmacokinetic profile, with low inter-subject variability. Additionally, MyoKardia initiated an open label, … Web31 mrt. 2024 · Mavacamten - Britol Myers Squibb/MyoKardia Alternative Names: BMS-986427; Camzyos; CamzyosTM; HCM 1; MAVA-Bristol Myers Squibb/Myokardia; MYK 461; SAR-439152 Latest Information Update: 31 Mar 2024 Price : $50 * Buy Profile Adis is an information provider. We do not sell or distribute actual drugs.
Web2 mei 2016 · MYK-461 is the Company’s lead product candidate and the first therapy designed to target the underlying cause of HCM. MyoKardia’s proposed initial indication for MYK-461 is oHCM. ... and indicate that MYK-461 is well tolerated with dose-proportional pharmacokinetics. WebMYK-461 is a myosin inhibitor that selectively decreases the ATPase activity of cardiac myosin heavy chain, thus it is potentially for the treatment of hypertrophic …
WebA Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left ... Summary. The purpose of this phase 2 open-label pilot study is to evaluate the efficacy, pharmacokinetics (PK), pharmacodynamics (PD), safety, and tolerability of MYK-461 in subjects with symptomatic HCM and LVOT … WebWe use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.
WebAdministers Grant ... the kings of wessex academy wikipediaWeb6 okt. 2015 · About MYK-461 MYK-461 is an orally administered small molecule that reduces left ventricular contractility. MyoKardia is currently evaluating MYK-461 in three Phase 1 clinical trials, which are primarily designed to evaluate safety and tolerability of oral doses of MYK-461 and are expected to provide data on its pharmacokinetic and … the kings of wessex academy cheddarWeb14 dec. 2016 · MYK-461 is a recently-described, mechanistically novel small molecule that acts at the sarcomere to specifically inhibit contractility that has been proposed as a … the king soldier poet quizWebMYK-461 is a drug that may be useful in the treatment of hypertrophic cardiomyopathy. Cardiomyopathy is a disorder of the heart muscle. Hypertrophic cardiomyopathy (HCM)is a genetic condition where the heart muscle becomes thickened. the kings of wessexWeb3 mrt. 2015 · The Phase 1 clinical trial will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating single oral doses of MYK-461 in healthy volunteers. the king soldier poet testWeb31 aug. 2024 · In a transgenic mouse model of HCM, introducing human disease-causing mutations into the murine α-cardiac myosin heavy chain gene, Green et al. demonstrated that MYK-461 caused a dose-dependent reduction in fractional shortening of cardiac muscle with no measurable effect on skeletal muscle despite its low affinity demonstrated in … the kings of wrestlingWeb18 mrt. 2024 · Mavacamten (previously known as MYK-461) is a small molecule identified by MyoKardia (acquired by Bristol Myers Squibb) in a screening, with the objective to … the kings of wessex school